Tourette syndrome, associated conditions and the complexities of treatment
Identifieur interne : 000418 ( Istex/Corpus ); précédent : 000417; suivant : 000419Tourette syndrome, associated conditions and the complexities of treatment
Auteurs : Mary M. RobertsonSource :
- Brain [ 0006-8950 ] ; 2000-03.
English descriptors
- KwdEn :
- 5-HT = 5-hydroxytryptamine, ADHD = attention deficit hyperactivity disorder, BNF = British National Formulary, CCEI = Crown Crisp Experimental Index, DBT = double-blind trial, DSMs = Diagnostic and Statistical Manuals, EPSE = extrapyramidal side-effect, GAD = generalized anxiety disorder, MDD = major depressive disorder, NMS = neuroleptic malignant syndrome, NOSI = non-obscene complex socially inappropriate behaviours, OCB = obsessive–compulsive behaviour, OCD = obsessive–compulsive disorder, OCS = obsessive–compulsive symptoms, PANDAS = paediatric autoimmune neuropsychiatric disorders associated with group A β-haemolytic streptococcal infections, SIB = self-injurious behaviour, SSRI = selective serotonin reuptake inhibitor, TCA = tricyclic antidepressant, TD = tardive dyskinesia, TS = Tourette syndrome, Tourette syndrome, YGTSS = Yale Global Tic Severity Scale, clinical phenomenology, psychopathology, treatment.
Abstract
Tourette syndrome (TS) is characterized by multiple motor tics plus one or more vocal (phonic) tics, which characteristically wax and wane. It can no longer be considered the rare and bizarre syndrome that it was once thought to be. The concepts surrounding TS, and our understanding of it, are also becoming increasingly complex and, in some individuals, TS is now recognized to be associated with a wide variety of associated behaviours and psychopathologies. It is suggested that TS is heterogeneous from a variety of standpoints including clinical presentation and psychopathology, and thus neuropharmacological responses and possibly even aetiological and genetic mechanisms. In this paper, mention is made of recent findings in epidemiology and genetics, highlighting the complexities of the disorder; these have been chosen because findings in both areas have clinical and management implications. The literature on the clinical manifestations, associated behaviours, psychopathology (and/or comorbid conditions) and management, in particular, is reviewed in detail.
Url:
DOI: 10.1093/brain/123.3.425
Links to Exploration step
ISTEX:E8165284D12B234DC0E4C5534C5F229918A66162Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tourette syndrome, associated conditions and the complexities of treatment</title><author wicri:is="90%"><name sortKey="Robertson, Mary M" sort="Robertson, Mary M" uniqKey="Robertson M" first="Mary M." last="Robertson">Mary M. Robertson</name><affiliation><mods:affiliation>Department of Psychiatry and Behavioural Sciences, University College and The National Hospital for Neurology and Neurosurgery, London, UK</mods:affiliation></affiliation><affiliation><mods:affiliation>Professor Mary M. Robertson, Department of Psychiatry and Behavioural Sciences, University College London, 2nd Floor, Wolfson Building, 48 Riding House Street, London W1N 8AA, UK</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E8165284D12B234DC0E4C5534C5F229918A66162</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1093/brain/123.3.425</idno><idno type="url">https://api.istex.fr/document/E8165284D12B234DC0E4C5534C5F229918A66162/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000418</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000418</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Tourette syndrome, associated conditions and the complexities of treatment</title><author wicri:is="90%"><name sortKey="Robertson, Mary M" sort="Robertson, Mary M" uniqKey="Robertson M" first="Mary M." last="Robertson">Mary M. Robertson</name><affiliation><mods:affiliation>Department of Psychiatry and Behavioural Sciences, University College and The National Hospital for Neurology and Neurosurgery, London, UK</mods:affiliation></affiliation><affiliation><mods:affiliation>Professor Mary M. Robertson, Department of Psychiatry and Behavioural Sciences, University College London, 2nd Floor, Wolfson Building, 48 Riding House Street, London W1N 8AA, UK</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain</title><title level="j" type="abbrev">Brain</title><idno type="ISSN">0006-8950</idno><idno type="eISSN">1460-2156</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2000-03">2000-03</date><biblScope unit="volume">123</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="425">425</biblScope><biblScope unit="page" to="462">462</biblScope></imprint><idno type="ISSN">0006-8950</idno></series><idno type="istex">E8165284D12B234DC0E4C5534C5F229918A66162</idno><idno type="DOI">10.1093/brain/123.3.425</idno><idno type="PII">1460-2156</idno><idno type="local">1230425</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8950</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5-HT = 5-hydroxytryptamine</term><term>ADHD = attention deficit hyperactivity disorder</term><term>BNF = British National Formulary</term><term>CCEI = Crown Crisp Experimental Index</term><term>DBT = double-blind trial</term><term>DSMs = Diagnostic and Statistical Manuals</term><term>EPSE = extrapyramidal side-effect</term><term>GAD = generalized anxiety disorder</term><term>MDD = major depressive disorder</term><term>NMS = neuroleptic malignant syndrome</term><term>NOSI = non-obscene complex socially inappropriate behaviours</term><term>OCB = obsessive–compulsive behaviour</term><term>OCD = obsessive–compulsive disorder</term><term>OCS = obsessive–compulsive symptoms</term><term>PANDAS = paediatric autoimmune neuropsychiatric disorders associated with group A β-haemolytic streptococcal infections</term><term>SIB = self-injurious behaviour</term><term>SSRI = selective serotonin reuptake inhibitor</term><term>TCA = tricyclic antidepressant</term><term>TD = tardive dyskinesia</term><term>TS = Tourette syndrome</term><term>Tourette syndrome</term><term>YGTSS = Yale Global Tic Severity Scale</term><term>clinical phenomenology</term><term>psychopathology</term><term>treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tourette syndrome (TS) is characterized by multiple motor tics plus one or more vocal (phonic) tics, which characteristically wax and wane. It can no longer be considered the rare and bizarre syndrome that it was once thought to be. The concepts surrounding TS, and our understanding of it, are also becoming increasingly complex and, in some individuals, TS is now recognized to be associated with a wide variety of associated behaviours and psychopathologies. It is suggested that TS is heterogeneous from a variety of standpoints including clinical presentation and psychopathology, and thus neuropharmacological responses and possibly even aetiological and genetic mechanisms. In this paper, mention is made of recent findings in epidemiology and genetics, highlighting the complexities of the disorder; these have been chosen because findings in both areas have clinical and management implications. The literature on the clinical manifestations, associated behaviours, psychopathology (and/or comorbid conditions) and management, in particular, is reviewed in detail.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>Mary M. Robertson</name><affiliations><json:string>Department of Psychiatry and Behavioural Sciences, University College and The National Hospital for Neurology and Neurosurgery, London, UK</json:string><json:string>Professor Mary M. Robertson, Department of Psychiatry and Behavioural Sciences, University College London, 2nd Floor, Wolfson Building, 48 Riding House Street, London W1N 8AA, UK</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Tourette syndrome</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinical phenomenology</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>psychopathology</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>treatment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ADHD = attention deficit hyperactivity disorder</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>BNF = British National Formulary</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>CCEI = Crown Crisp Experimental Index</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>DBT = double-blind trial</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>DSMs = Diagnostic and Statistical Manuals</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>EPSE = extrapyramidal side-effect</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>GAD = generalized anxiety disorder</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>5-HT = 5-hydroxytryptamine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MDD = major depressive disorder</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>NMS = neuroleptic malignant syndrome</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>NOSI = non-obscene complex socially inappropriate behaviours</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>OCB = obsessive–compulsive behaviour</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>OCD = obsessive–compulsive disorder</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>OCS = obsessive–compulsive symptoms</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>PANDAS = paediatric autoimmune neuropsychiatric disorders associated with group A β-haemolytic streptococcal infections</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>SIB = self-injurious behaviour</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>SSRI = selective serotonin reuptake inhibitor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>TCA = tricyclic antidepressant</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>TD = tardive dyskinesia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>TS = Tourette syndrome</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>YGTSS = Yale Global Tic Severity Scale</value></json:item></subject><language><json:string>eng</json:string></language><originalGenre><json:string>other</json:string></originalGenre><abstract>Tourette syndrome (TS) is characterized by multiple motor tics plus one or more vocal (phonic) tics, which characteristically wax and wane. It can no longer be considered the rare and bizarre syndrome that it was once thought to be. The concepts surrounding TS, and our understanding of it, are also becoming increasingly complex and, in some individuals, TS is now recognized to be associated with a wide variety of associated behaviours and psychopathologies. It is suggested that TS is heterogeneous from a variety of standpoints including clinical presentation and psychopathology, and thus neuropharmacological responses and possibly even aetiological and genetic mechanisms. In this paper, mention is made of recent findings in epidemiology and genetics, highlighting the complexities of the disorder; these have been chosen because findings in both areas have clinical and management implications. The literature on the clinical manifestations, associated behaviours, psychopathology (and/or comorbid conditions) and management, in particular, is reviewed in detail.</abstract><qualityIndicators><score>8.848</score><pdfVersion>1.2</pdfVersion><pdfPageSize>612 x 791 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>25</keywordCount><abstractCharCount>1073</abstractCharCount><pdfWordCount>29055</pdfWordCount><pdfCharCount>183463</pdfCharCount><pdfPageCount>38</pdfPageCount><abstractWordCount>154</abstractWordCount></qualityIndicators><title>Tourette syndrome, associated conditions and the complexities of treatment</title><pii><json:string>1460-2156</json:string></pii><genre><json:string>other</json:string></genre><host><volume>123</volume><publisherId><json:string>brainj</json:string></publisherId><pages><last>462</last><first>425</first></pages><issn><json:string>0006-8950</json:string></issn><issue>3</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1460-2156</json:string></eissn><title>Brain</title></host><publicationDate>2000</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1093/brain/123.3.425</json:string></doi><id>E8165284D12B234DC0E4C5534C5F229918A66162</id><score>0.07058499</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/E8165284D12B234DC0E4C5534C5F229918A66162/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/E8165284D12B234DC0E4C5534C5F229918A66162/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E8165284D12B234DC0E4C5534C5F229918A66162/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Tourette syndrome, associated conditions and the complexities of treatment</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Oxford University Press</publisher><availability><p>© Oxford University Press 2000</p></availability><date>2000</date></publicationStmt><notesStmt><note>Professor Mary M. Robertson, Department of Psychiatry and Behavioural Sciences, University College London, 2nd Floor, Wolfson Building, 48 Riding House Street, London W1N 8AA, UK E-mail: rejummr@ucl.ac.uk</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Tourette syndrome, associated conditions and the complexities of treatment</title><author xml:id="author-1"><persName><forename type="first">Mary M.</forename><surname>Robertson</surname></persName><affiliation>Department of Psychiatry and Behavioural Sciences, University College and The National Hospital for Neurology and Neurosurgery, London, UK</affiliation><affiliation>Professor Mary M. Robertson, Department of Psychiatry and Behavioural Sciences, University College London, 2nd Floor, Wolfson Building, 48 Riding House Street, London W1N 8AA, UK</affiliation></author></analytic><monogr><title level="j">Brain</title><title level="j" type="abbrev">Brain</title><idno type="pISSN">0006-8950</idno><idno type="eISSN">1460-2156</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2000-03"></date><biblScope unit="volume">123</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="425">425</biblScope><biblScope unit="page" to="462">462</biblScope></imprint></monogr><idno type="istex">E8165284D12B234DC0E4C5534C5F229918A66162</idno><idno type="DOI">10.1093/brain/123.3.425</idno><idno type="PII">1460-2156</idno><idno type="local">1230425</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Tourette syndrome (TS) is characterized by multiple motor tics plus one or more vocal (phonic) tics, which characteristically wax and wane. It can no longer be considered the rare and bizarre syndrome that it was once thought to be. The concepts surrounding TS, and our understanding of it, are also becoming increasingly complex and, in some individuals, TS is now recognized to be associated with a wide variety of associated behaviours and psychopathologies. It is suggested that TS is heterogeneous from a variety of standpoints including clinical presentation and psychopathology, and thus neuropharmacological responses and possibly even aetiological and genetic mechanisms. In this paper, mention is made of recent findings in epidemiology and genetics, highlighting the complexities of the disorder; these have been chosen because findings in both areas have clinical and management implications. The literature on the clinical manifestations, associated behaviours, psychopathology (and/or comorbid conditions) and management, in particular, is reviewed in detail.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>KWD</head><item><term>Tourette syndrome</term></item><item><term>clinical phenomenology</term></item><item><term>psychopathology</term></item><item><term>treatment</term></item></list></keywords></textClass><textClass xml:lang="en"><keywords scheme="keyword"><list><head>ABR</head><item><term>ADHD = attention deficit hyperactivity disorder</term></item><item><term>BNF = British National Formulary</term></item><item><term>CCEI = Crown Crisp Experimental Index</term></item><item><term>DBT = double-blind trial</term></item><item><term>DSMs = Diagnostic and Statistical Manuals</term></item><item><term>EPSE = extrapyramidal side-effect</term></item><item><term>GAD = generalized anxiety disorder</term></item><item><term>5-HT = 5-hydroxytryptamine</term></item><item><term>MDD = major depressive disorder</term></item><item><term>NMS = neuroleptic malignant syndrome</term></item><item><term>NOSI = non-obscene complex socially inappropriate behaviours</term></item><item><term>OCB = obsessive–compulsive behaviour</term></item><item><term>OCD = obsessive–compulsive disorder</term></item><item><term>OCS = obsessive–compulsive symptoms</term></item><item><term>PANDAS = paediatric autoimmune neuropsychiatric disorders associated with group A β-haemolytic streptococcal infections</term></item><item><term>SIB = self-injurious behaviour</term></item><item><term>SSRI = selective serotonin reuptake inhibitor</term></item><item><term>TCA = tricyclic antidepressant</term></item><item><term>TD = tardive dyskinesia</term></item><item><term>TS = Tourette syndrome</term></item><item><term>YGTSS = Yale Global Tic Severity Scale</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2000-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/E8165284D12B234DC0E4C5534C5F229918A66162/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="US-ASCII"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article xml:lang="en" article-type="other"><front><journal-meta><journal-id journal-id-type="hwp">brain</journal-id><journal-id journal-id-type="nlm-ta">Brain</journal-id><journal-id journal-id-type="publisher-id">brainj</journal-id><journal-title>Brain</journal-title><abbrev-journal-title abbrev-type="publisher">Brain</abbrev-journal-title><issn pub-type="ppub">0006-8950</issn><issn pub-type="epub">1460-2156</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="other">1230425</article-id><article-id pub-id-type="doi">10.1093/brain/123.3.425</article-id><article-id pub-id-type="pii">1460-2156</article-id><title-group><article-title>Tourette syndrome, associated conditions and the complexities of treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Robertson</surname><given-names>Mary M.</given-names></name></contrib><aff>Department of Psychiatry and Behavioural Sciences, University College and The National Hospital for Neurology and Neurosurgery, London, UK</aff></contrib-group><author-notes><corresp>Professor Mary M. Robertson, Department of Psychiatry and Behavioural Sciences, University College London, 2nd Floor, Wolfson Building, 48 Riding House Street, London W1N 8AA, UK E-mail: <ext-link xlink:href="rejummr@ucl.ac.uk" ext-link-type="email">rejummr@ucl.ac.uk</ext-link></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2000</year></pub-date><volume>123</volume><issue>3</issue><fpage>425</fpage><lpage>462</lpage><history><date date-type="accepted"><day>13</day><month>09</month><year>1999</year></date><date date-type="received"><day>02</day><month>09</month><year>1998</year></date><date date-type="rev-recd"><day>18</day><month>05</month><year>1999</year></date></history><copyright-statement>© Oxford University Press 2000</copyright-statement><copyright-year>2000</copyright-year><abstract xml:lang="en"><p>Tourette syndrome (TS) is characterized by multiple motor tics plus one or more vocal (phonic) tics, which characteristically wax and wane. It can no longer be considered the rare and bizarre syndrome that it was once thought to be. The concepts surrounding TS, and our understanding of it, are also becoming increasingly complex and, in some individuals, TS is now recognized to be associated with a wide variety of associated behaviours and psychopathologies. It is suggested that TS is heterogeneous from a variety of standpoints including clinical presentation and psychopathology, and thus neuropharmacological responses and possibly even aetiological and genetic mechanisms. In this paper, mention is made of recent findings in epidemiology and genetics, highlighting the complexities of the disorder; these have been chosen because findings in both areas have clinical and management implications. The literature on the clinical manifestations, associated behaviours, psychopathology (and/or comorbid conditions) and management, in particular, is reviewed in detail.</p></abstract><kwd-group kwd-group-type="KWD" xml:lang="en"><kwd>Tourette syndrome</kwd><kwd>clinical phenomenology</kwd><kwd>psychopathology</kwd><kwd>treatment</kwd></kwd-group><kwd-group kwd-group-type="ABR" xml:lang="en"><kwd>ADHD = attention deficit hyperactivity disorder</kwd><kwd>BNF = British National Formulary</kwd><kwd>CCEI = Crown Crisp Experimental Index</kwd><kwd>DBT = double-blind trial</kwd><kwd>DSMs = Diagnostic and Statistical Manuals</kwd><kwd>EPSE = extrapyramidal side-effect</kwd><kwd>GAD = generalized anxiety disorder</kwd><kwd>5-HT = 5-hydroxytryptamine</kwd><kwd>MDD = major depressive disorder</kwd><kwd>NMS = neuroleptic malignant syndrome</kwd><kwd>NOSI = non-obscene complex socially inappropriate behaviours</kwd><kwd>OCB = obsessive–compulsive behaviour</kwd><kwd>OCD = obsessive–compulsive disorder</kwd><kwd>OCS = obsessive–compulsive symptoms</kwd><kwd>PANDAS = paediatric autoimmune neuropsychiatric disorders associated with group A β-haemolytic streptococcal infections</kwd><kwd>SIB = self-injurious behaviour</kwd><kwd>SSRI = selective serotonin reuptake inhibitor</kwd><kwd>TCA = tricyclic antidepressant</kwd><kwd>TD = tardive dyskinesia</kwd><kwd>TS = Tourette syndrome</kwd><kwd>YGTSS = Yale Global Tic Severity Scale</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>hwp-legacy-fpage</meta-name><meta-value>425</meta-value></custom-meta><custom-meta><meta-name>hwp-legacy-dochead</meta-name><meta-value>Invited review</meta-value></custom-meta></custom-meta-wrap></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Tourette syndrome, associated conditions and the complexities of treatment</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Tourette syndrome, associated conditions and the complexities of treatment</title></titleInfo><name type="personal"><namePart type="given">Mary M.</namePart><namePart type="family">Robertson</namePart><affiliation>Department of Psychiatry and Behavioural Sciences, University College and The National Hospital for Neurology and Neurosurgery, London, UK</affiliation><affiliation>Professor Mary M. Robertson, Department of Psychiatry and Behavioural Sciences, University College London, 2nd Floor, Wolfson Building, 48 Riding House Street, London W1N 8AA, UK</affiliation></name><typeOfResource>text</typeOfResource><genre type="other" displayLabel="other"></genre><originInfo><publisher>Oxford University Press</publisher><dateIssued encoding="w3cdtf">2000-03</dateIssued><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Tourette syndrome (TS) is characterized by multiple motor tics plus one or more vocal (phonic) tics, which characteristically wax and wane. It can no longer be considered the rare and bizarre syndrome that it was once thought to be. The concepts surrounding TS, and our understanding of it, are also becoming increasingly complex and, in some individuals, TS is now recognized to be associated with a wide variety of associated behaviours and psychopathologies. It is suggested that TS is heterogeneous from a variety of standpoints including clinical presentation and psychopathology, and thus neuropharmacological responses and possibly even aetiological and genetic mechanisms. In this paper, mention is made of recent findings in epidemiology and genetics, highlighting the complexities of the disorder; these have been chosen because findings in both areas have clinical and management implications. The literature on the clinical manifestations, associated behaviours, psychopathology (and/or comorbid conditions) and management, in particular, is reviewed in detail.</abstract><note type="author-notes">Professor Mary M. Robertson, Department of Psychiatry and Behavioural Sciences, University College London, 2nd Floor, Wolfson Building, 48 Riding House Street, London W1N 8AA, UK E-mail: rejummr@ucl.ac.uk</note><subject lang="en"><genre>KWD</genre><topic>Tourette syndrome</topic><topic>clinical phenomenology</topic><topic>psychopathology</topic><topic>treatment</topic></subject><subject lang="en"><genre>ABR</genre><topic>ADHD = attention deficit hyperactivity disorder</topic><topic>BNF = British National Formulary</topic><topic>CCEI = Crown Crisp Experimental Index</topic><topic>DBT = double-blind trial</topic><topic>DSMs = Diagnostic and Statistical Manuals</topic><topic>EPSE = extrapyramidal side-effect</topic><topic>GAD = generalized anxiety disorder</topic><topic>5-HT = 5-hydroxytryptamine</topic><topic>MDD = major depressive disorder</topic><topic>NMS = neuroleptic malignant syndrome</topic><topic>NOSI = non-obscene complex socially inappropriate behaviours</topic><topic>OCB = obsessive–compulsive behaviour</topic><topic>OCD = obsessive–compulsive disorder</topic><topic>OCS = obsessive–compulsive symptoms</topic><topic>PANDAS = paediatric autoimmune neuropsychiatric disorders associated with group A β-haemolytic streptococcal infections</topic><topic>SIB = self-injurious behaviour</topic><topic>SSRI = selective serotonin reuptake inhibitor</topic><topic>TCA = tricyclic antidepressant</topic><topic>TD = tardive dyskinesia</topic><topic>TS = Tourette syndrome</topic><topic>YGTSS = Yale Global Tic Severity Scale</topic></subject><relatedItem type="host"><titleInfo><title>Brain</title></titleInfo><titleInfo type="abbreviated"><title>Brain</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0006-8950</identifier><identifier type="eISSN">1460-2156</identifier><identifier type="PublisherID">brainj</identifier><identifier type="PublisherID-hwp">brain</identifier><identifier type="PublisherID-nlm-ta">Brain</identifier><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>425</start><end>462</end></extent></part></relatedItem><identifier type="istex">E8165284D12B234DC0E4C5534C5F229918A66162</identifier><identifier type="DOI">10.1093/brain/123.3.425</identifier><identifier type="PII">1460-2156</identifier><identifier type="local">1230425</identifier><accessCondition type="use and reproduction" contentType="copyright">© Oxford University Press 2000</accessCondition><recordInfo><recordContentSource>OUP</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/DanceTherParkinsonV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000418 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000418 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= DanceTherParkinsonV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:E8165284D12B234DC0E4C5534C5F229918A66162
|texte= Tourette syndrome, associated conditions and the complexities of treatment
}}
| This area was generated with Dilib version V0.6.35. |  |